News & Media

Recent updates from Arcutis.

March 4, 2024

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

March 4, 2024

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

February 29, 2024

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

February 28, 2024

Arcutis Announces Pricing of $150 Million Public Offering

February 28, 2024

Arcutis Announces Proposed Public Offering

February 28, 2024

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

February 27, 2024

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 16, 2024

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

February 6, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 31, 2024

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

January 29, 2024

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

January 22, 2024

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download